查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878842

ACE抑制劑市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、藥物、劑型、應用、最終用戶、地區和競爭格局分類，2020-2030年預測

ACE Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Drug, By Dosage Form, By Application, By End user, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球血管張力素轉換酶抑制劑（ACE抑制劑）市場規模為69.4億美元，預計2030年將以5.75%的複合年成長率成長至97.1億美元。血管張力素轉換酶抑制劑是一類主要用於放鬆血管、降低血壓的藥物，進而治療高血壓、心臟衰竭和慢性腎臟病等疾病。推動ACE抑制劑市場成長的主要因素是全球心血管疾病和高血壓盛行率的上升以及人口老化的加劇。

市場概覽
預測期 2026-2030
2024年市場規模 69.4億美元
2030年市場規模 97.1億美元
2025-2030年複合年成長率 5.75%
成長最快的細分市場 口服錠劑
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球ACE抑制劑市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依類型（含巰基的試劑、含二羧酸鹽的試劑、含膦酸鹽的試劑）
    • 依藥物分類（雷米普利、依那普利、貝那普利、福辛普利、卡托普利、莫昔普利、其他）
    • 依劑型（口服錠劑、口服溶液）
    • 依應用領域（心臟衰竭、慢性腎臟病、高血壓、糖尿病、心臟病發作、其他）
    • 按最終用戶（醫院、線上藥局、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美ACE抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲ACE抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區ACE抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲ACE抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲ACE抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球ACE抑制劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Pfizer Inc
  • Novartis AG
  • Johnson & Johnson
  • Merck KGaA
  • Sanofi SA
  • Bayer AG
  • United Therapeutics Corporation
  • Teva Pharmaceutical Industry
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals Company

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 20968

The Global ACE Inhibitors Market, valued at USD 6.94 Billion in 2024, is projected to experience a CAGR of 5.75% to reach USD 9.71 Billion by 2030. Angiotensin-converting enzyme (ACE) inhibitors constitute a class of pharmaceutical agents primarily utilized to relax blood vessels and reduce blood pressure, thereby managing conditions such as hypertension, heart failure, and chronic kidney disease. The market for these inhibitors is principally driven by the rising global prevalence of cardiovascular diseases and hypertension, alongside an expanding aging population.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.94 Billion
Market Size 2030USD 9.71 Billion
CAGR 2025-20305.75%
Fastest Growing SegmentOral Tablets
Largest MarketNorth America

Key Market Drivers

The increasing global burden of cardiovascular diseases represents a fundamental driver for the ACE inhibitors market. The widespread prevalence of conditions such as hypertension and heart failure necessitates effective and accessible therapeutic options. These illnesses not only reduce quality of life but also place substantial strain on healthcare systems worldwide. According to the "Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023" published in JACC, in September 2025, the number of prevalent cases of cardiovascular disease reached 626 million globally in 2023, underscoring the vast and growing patient population requiring management for these conditions. This elevated disease burden directly fuels the demand for ACE inhibitors, which are cornerstone treatments for various cardiovascular ailments, driving sustained market expansion.

Key Market Challenges

The potential for adverse effects associated with angiotensin-converting enzyme (ACE) inhibitors presents a significant impediment to market expansion. These side effects, including persistent cough, hyperkalemia, and rare angioedema, frequently lead to patient non-adherence or complete discontinuation of therapy. Such reactions directly diminish the patient base that continues to utilize ACE inhibitor treatments. According to research published in *Frontiers in Cardiovascular Medicine* in 2023, approximately 23.0% of patients prescribed ACE inhibitors were non-persistent with their treatment. This substantial rate of non-persistence, often influenced by the challenges of managing adverse drug reactions, directly limits the therapeutic lifespan of ACE inhibitors for individual patients.

Key Market Trends

The growing adoption of fixed-dose combination therapies represents a pivotal trend in the Global ACE Inhibitors Market. These single-pill combinations enhance patient adherence by simplifying complex treatment regimens, which is crucial for managing chronic conditions like hypertension and heart failure. Such formulations improve therapeutic outcomes by ensuring consistent medication intake. For instance, according to a study published in *J Clin Hypertens (Greenwich)* in August 2025, patients receiving angiotensin-converting enzyme inhibitor or angiotensin receptor blocker combination therapies exhibited the highest adherence rate at 79.18% in 2022-2023, compared to other antihypertensive drug classes. This improvement in adherence directly contributes to better disease control and sustained demand for ACE inhibitor-inclusive fixed-dose combinations.

Key Market Players

  • Pfizer Inc
  • Novartis AG
  • Johnson & Johnson
  • Merck KGaA
  • Sanofi S.A
  • Bayer AG
  • United Therapeutics Corporation
  • Teva Pharmaceutical Industry
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals Company

Report Scope:

In this report, the Global ACE Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

ACE Inhibitors Market, By Type:

  • Sulfhydryl-containing Agents
  • Dicarboxylate-containing Agents.
  • Phosphonate-containing Agents

ACE Inhibitors Market, By Drug:

  • Ramipril
  • Enalapril
  • Benazepril
  • Fosinopril
  • Captopril
  • Moexipril
  • Others

ACE Inhibitors Market, By Dosage Form:

  • Oral Tablets
  • Oral Solutions

ACE Inhibitors Market, By Application:

  • Heart Failure
  • Chronic Kidney Disease
  • Hypertension
  • Diabetes
  • Heart Attack
  • Others

ACE Inhibitors Market, By End user:

  • Hospitals
  • Online Drug Stores
  • Others

ACE Inhibitors Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global ACE Inhibitors Market.

Available Customizations:

Global ACE Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global ACE Inhibitors Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents., Phosphonate-containing Agents)
    • 5.2.2. By Drug (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others)
    • 5.2.3. By Dosage Form (Oral Tablets, Oral Solutions)
    • 5.2.4. By Application (Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Others)
    • 5.2.5. By End user (Hospitals, Online Drug Stores, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map

6. North America ACE Inhibitors Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Drug
    • 6.2.3. By Dosage Form
    • 6.2.4. By Application
    • 6.2.5. By End user
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States ACE Inhibitors Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Drug
        • 6.3.1.2.3. By Dosage Form
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End user
    • 6.3.2. Canada ACE Inhibitors Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Drug
        • 6.3.2.2.3. By Dosage Form
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End user
    • 6.3.3. Mexico ACE Inhibitors Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Drug
        • 6.3.3.2.3. By Dosage Form
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End user

7. Europe ACE Inhibitors Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Drug
    • 7.2.3. By Dosage Form
    • 7.2.4. By Application
    • 7.2.5. By End user
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany ACE Inhibitors Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Drug
        • 7.3.1.2.3. By Dosage Form
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End user
    • 7.3.2. France ACE Inhibitors Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Drug
        • 7.3.2.2.3. By Dosage Form
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End user
    • 7.3.3. United Kingdom ACE Inhibitors Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Drug
        • 7.3.3.2.3. By Dosage Form
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End user
    • 7.3.4. Italy ACE Inhibitors Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Drug
        • 7.3.4.2.3. By Dosage Form
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End user
    • 7.3.5. Spain ACE Inhibitors Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Drug
        • 7.3.5.2.3. By Dosage Form
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End user

8. Asia Pacific ACE Inhibitors Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Drug
    • 8.2.3. By Dosage Form
    • 8.2.4. By Application
    • 8.2.5. By End user
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China ACE Inhibitors Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Drug
        • 8.3.1.2.3. By Dosage Form
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End user
    • 8.3.2. India ACE Inhibitors Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Drug
        • 8.3.2.2.3. By Dosage Form
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End user
    • 8.3.3. Japan ACE Inhibitors Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Drug
        • 8.3.3.2.3. By Dosage Form
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End user
    • 8.3.4. South Korea ACE Inhibitors Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Drug
        • 8.3.4.2.3. By Dosage Form
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End user
    • 8.3.5. Australia ACE Inhibitors Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Drug
        • 8.3.5.2.3. By Dosage Form
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End user

9. Middle East & Africa ACE Inhibitors Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Drug
    • 9.2.3. By Dosage Form
    • 9.2.4. By Application
    • 9.2.5. By End user
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia ACE Inhibitors Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Drug
        • 9.3.1.2.3. By Dosage Form
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End user
    • 9.3.2. UAE ACE Inhibitors Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Drug
        • 9.3.2.2.3. By Dosage Form
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End user
    • 9.3.3. South Africa ACE Inhibitors Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Drug
        • 9.3.3.2.3. By Dosage Form
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End user

10. South America ACE Inhibitors Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Drug
    • 10.2.3. By Dosage Form
    • 10.2.4. By Application
    • 10.2.5. By End user
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil ACE Inhibitors Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Drug
        • 10.3.1.2.3. By Dosage Form
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End user
    • 10.3.2. Colombia ACE Inhibitors Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Drug
        • 10.3.2.2.3. By Dosage Form
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End user
    • 10.3.3. Argentina ACE Inhibitors Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Drug
        • 10.3.3.2.3. By Dosage Form
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global ACE Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Johnson & Johnson
  • 15.4. Merck KGaA
  • 15.5. Sanofi S.A
  • 15.6. Bayer AG
  • 15.7. United Therapeutics Corporation
  • 15.8. Teva Pharmaceutical Industry
  • 15.9. Bristol-Myers Squibb
  • 15.10. Takeda Pharmaceuticals Company

16. Strategic Recommendations

17. About Us & Disclaimer